Nootropics 99% Nsi-189 Free Base Powder CAS 1270138-40-3 Nsi-189 Free Base

• Customization: Available
• Powder: Yes
• Customized: Non-Customized
• Model NO.: tzsw20250316
• Certification: GMP, ISO 9001, USP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Active Ingredient: Nsi-189 Free Base
• Grade Standard: Medicine Grade
• Shelf Life: 2 Years Proper Storage
• Storage: Cool Dry Place
• MW: 366.5
• Type of Product: Auxiliaries and Other Medicinal Chemicals
• Transport Package: 1kg Per Foil Bag, 10 Bags Per Carton. 25 Kg Per Dr
• Specification: 99% min
• Origin: Shaanxi China
• Production Capacity: 20000

Product Description

                       

Nootropics 99% NSI-189 Free Base Powder CAS 1270138-40-3 Nsi-189 Free Base

Product Name	High Purity Raw Nootropics 99% Nsi-189 Free Base Powder CAS 1270138-40-3 Nsi-189 Free Base
Appearance	White powder
Molecular formula	C22H30N4O
Molecular Weight	366.5
Keywords	Nsi-189 Free Base;Nsi-189 Free Base Powder;Nsi-189 Free Base Powder CAS 1270138-40-3
Shelf Life	24 months when properly stored
Storage	Keep in a cool, dry, dark location

What is NSI-189 free base?
NSI-189 is a nootropic and neurogenic research chemical derived from nicotinamide and pyrazine .
NSI-189 has been shown to stimulate neurogenesis of human hippocampus-derived neural stem cells in vitro and in vivo.
The hippocampus is responsible for the consolidation of information from short-term memory to long-term memory, along with spatial navigation, nootropics neurogenic drugs nsi-189.

Function of NSI-189 free base
1.Nsi-189 can Enhance cognition and memory formation 
2.Nsi-189 can Anxiolytic properties 
3.Nsi-189 can Anti-depressive effect
4.Nsi-189 can Treatment of Alzheimer's and Parkinson's disease 
5.Nsi-189 can Increase coordination 6.Nsi-189 can Improves mood
7.Nsi-189 can Help fight fatigue 
8.Nsi-189 can Prevent oxidation within the brain 
9.Nsi-189 can Treat alcohol related brain damage.
 

Application of NSI-189 free base

NSI-189 is a proprietary new chemical entity that stimulates new neuron growth in the hippocampus, an area of the brain believed to be contributory in MDD and other conditions, such as Alzheimer's disease and Post-traumatic stress disorder (PTSD). Phase 1b of the clinical trial is to test the safety and tolerability of the depressed patients.